LC-MS / MS method for separating and determining genetic toxic impurities in ibrutinib

Through the LC-MS/MS method combined with gradient elution and mass spectrometry detection, the problem of separation detection of impurities SM3a and Z6k in ibrutinib is solved, and the impurity control with high efficiency and strong sensitivity is achieved, meeting the limit requirements of drug quality control.

CN118914410APending Publication Date: 2024-11-08CHONGQING HUAPONT PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411321038.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art cannot effectively separate and detect impurities SM3a and impurities Z6k in ibrutinib, and the sensitivity of conventional methods cannot meet the limit requirements, and there is a lack of efficient detection methods for this drug.

Method used

The LC-MS/MS method was used to separate and detect genotoxic impurities in ibrutinib. The impurities were realized by reverse phase amide-bonded silica gel chromatography column, gradient elution program and mass spectrometry detection, combined with formic acid water and acetonitrile as mobile phase. Separation and identification of SM3a and impurity Z6k.

Benefits of technology

Effectively separate and identify impurities SM3a and impurities Z6k within 25 minutes, with detection limit as low as 5.6ng/ml, meeting the limit requirements of 23.5ppm, providing high sensitivity and accurate impurity control methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914410A_ABST
    Figure CN118914410A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to an LC-MS / MS method for separating and determining genotoxic impurities in ibrutinib. The genotoxic impurities comprise an impurity SM3a and / or an impurity Z6k. According to the LC-MS / MS method, reverse-phase amide bonded silica gel is adopted as a chromatographic column filling agent, formic acid water is adopted as a mobile phase A, acetonitrile is adopted as a mobile phase B, and genetic toxic impurities in ibrutinib are separated through gradient elution; a tandem quadrupole mass spectrometry detector is adopted for detection, and a chromatogram is obtained; and carrying out qualitative and quantitative analysis on the genotoxic impurities according to a chromatogram. The LC-MS / MS method capable of effectively determining the impurity SM3a and the impurity Z6k in the ibrutinib is provided for the first time, and the method is high in specificity, accuracy and sensitivity, simple and easy to operate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug analysis, and particularly relates to an LC-MS / MS method for separating and determining genotoxic impurities in ibrutinib. Background Art

[0002] Ibrutinib is the world's first approved Bruton's tyrosine kinase (BTK) inhibitor and an irreversible inhibitor. Ibrutinib has shown significant efficacy in the treatment of a variety of B-cell malignancies, especially in the field of hematological tumors, such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and Waldenstrom's macroglobulinemia (WM). Ibrutinib irreversibly inhibits the activity of BTK by covalently binding to the cysteine ​​residues at the BTK active site. BTK plays a key role in the B cell receptor (BCR) signaling pathway. Ibrutinib inhibits the malignant proliferation of tumor B cells and induces cell apoptosis by blocking this signaling pathway. At the same time, ibrutinib may also reduce the secretion of cell chemokines and proinflammatory cytokines, downregulate the expression level of the anti-apoptotic protein bcl-2 family, and further inhibit the growth, adhesion, invasion and migration of tumor cells. Therefore, ibrutinib plays an important role in the treatment of B-cell malignancies.

[0003] The structural formula of Ibrutinib is shown in Formula I. In the study of the synthesis process of Ibrutinib, it was found that the impurity SM is easily introduced during the synthesis process of Ibrutinib. 3a and impurity Z 6k SM 3a The structural formula of is shown in Formula II, impurity Z 6k The structural formula of is shown in Formula III.

[0004]

[0005] Impurity SM 3a and impurity Z 6k Both are genotoxic impurities with warning structures. The content of these two impurities needs to be strictly controlled during the synthesis and preparation of Ibrutinib. 3a and impurity Z 6kThe limit requirement is 23.5ppm, but the sensitivity of conventional LC or GC methods cannot meet the requirement at all. In the prior art, the patent with publication number CN104407067A discloses a liquid phase separation detection method for ibrutinib and its enantiomeric impurities, and discloses specific chromatographic conditions: using AD-H, 4.6mm X250mm, 5μm, chiral chromatographic column as the separation chromatographic column; using a mixed solvent of an alkane solvent and an alcohol solvent as the mobile phase, and the volume ratio of the alkane solvent to the alcohol solvent is 35:65. This invention uses high performance liquid chromatography to detect ibrutinib and its enantiomeric impurities, and under the conditions of this method, it is impossible to effectively separate and detect the impurity SM 3a and impurity Z 6k .

[0006] So far, no specific target has been found for the impurity SM in ibrutinib. 3a and impurity Z 6k Therefore, it is necessary to develop a convenient, fast and highly sensitive detection method for impurity SM 3a and impurity Z 6k control. Summary of the invention

[0007] In view of this, one of the objects of the present invention is to provide a method for separating genotoxic impurities in ibrutinib using LC-MS / MS, which can separate genotoxic impurities in ibrutinib within 25 minutes or more, providing support for the subsequent qualitative and quantitative analysis of impurities.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] Method for separating genotoxic impurities in ibrutinib using LC-MS / MS, wherein the genotoxic impurities include impurity SM 3a 、Impurity Z 6k Any one or two of the following; the structural formula of Ibrutinib is as shown in Formula I, the impurity SM 3a The structural formula is shown in Formula II, and the impurity Z 6k The structural formula is shown in Formula III; the LC-MS / MS method comprises: using reverse phase amide bonded silica gel as a chromatographic column filler, using formic acid water as a mobile phase A, and acetonitrile as a mobile phase B, and separating the genotoxic impurities in ibrutinib by gradient elution;

[0010]

[0011] Further, the gradient elution is set as follows:

[0012] 0min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30;

[0013] 6min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30;

[0014] 6.1min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50;

[0015] 10min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50;

[0016] 10.1min, the volume ratio of the mobile phase A to the mobile phase B is 1-3:99-97;

[0017] 20min, the volume ratio of the mobile phase A to the mobile phase B is 1-3:99-97;

[0018] 20.1min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30;

[0019] 25min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30.

[0020] Preferably, the gradient elution is set as follows:

[0021] 0min, the volume ratio of the mobile phase A to the mobile phase B is 58-62:42-38;

[0022] 6min, the volume ratio of the mobile phase A to the mobile phase B is 58-62:42-38;

[0023] 6.1min, the volume ratio of the mobile phase A to the mobile phase B is 38-42:62-58;

[0024] 10min, the volume ratio of the mobile phase A to the mobile phase B is 38-42:62-58;

[0025] 10.1min, the volume ratio of the mobile phase A to the mobile phase B is 1-2:99-98;

[0026] 20min, the volume ratio of the mobile phase A to the mobile phase B is 1-2:99-98;

[0027] 20.1min, the volume ratio of the mobile phase A to the mobile phase B is 58-62:42-38;

[0028] 25min, the volume ratio of the mobile phase A to the mobile phase B is 58-62:42-38.

[0029] Most preferably, the gradient elution is set as follows:

[0030] 0min, the volume ratio of the mobile phase A to the mobile phase B is 60:40;

[0031] 6min, the volume ratio of the mobile phase A to the mobile phase B is 60:40;

[0032] 6.1min, the volume ratio of the mobile phase A to the mobile phase B is 40:60;

[0033] 10 min, the volume ratio of the mobile phase A to the mobile phase B is 40:60;

[0034] 10.1min, the volume ratio of the mobile phase A to the mobile phase B is 1:99;

[0035] 20min, the volume ratio of the mobile phase A to the mobile phase B is 1:99;

[0036] 20.1min, the volume ratio of the mobile phase A to the mobile phase B is 60:40;

[0037] 25min, the volume ratio of the mobile phase A to the mobile phase B is 60:40.

[0038] Furthermore, the mobile phase A is a formic acid aqueous solution with a concentration of 0.05% to 0.2%.

[0039] Preferably, the mobile phase A is a 0.1% formic acid aqueous solution.

[0040] Furthermore, the column temperature of the chromatographic column is 30±2° C., and the flow rate of the mobile phase is 1±0.2 ml / min.

[0041] Preferably, the column temperature of the chromatographic column is 30° C., and the flow rate of the mobile phase is 1 ml / min.

[0042] Preferably, the specifications of the chromatographic column are 4.6 mm×150 mm, 5 μm.

[0043] As the most preferred, the chromatographic column is selected from SUPELCO RP-Amide 4.6mm×150mm, 5μm.

[0044] Preferably, the injection volume is 20 μl.

[0045] Preferably, the running time is 25 minutes.

[0046] The second object of the present invention is to provide a method for identifying whether ibrutinib contains genotoxic impurities, which can identify impurities with a concentration as low as 5.6 ng / ml, with a low detection limit and high sensitivity.

[0047] To achieve the above object, the present invention adopts the following technical solutions:

[0048] The method for identifying whether ibrutinib contains genotoxic impurities comprises the following steps:

[0049] (1) Separation: Separating the genotoxic impurities in ibrutinib using the aforementioned separation method;

[0050] (2) Detection: Detection is performed using a tandem quadrupole mass spectrometer to obtain a chromatogram;

[0051] (3) Identification: Compare the chromatographic behavior of the test sample with that of the reference sample to determine whether the test sample contains genotoxic impurities.

[0052] Furthermore, in step (2), multiple reaction detection is performed in positive ion mode using an electrospray ion source.

[0053] Further, a mass-to-charge ratio of 179.0→125.0 is used as the impurity SM 3a The detection ion pair is 457.1→303.1, and the impurity Z is used as 6k Detection ion pairs.

[0054] Furthermore, the mass spectrometry parameters specifically include: ESI ion source, MRM positive ion mode, nebulizer gas: 55±2psi, heating auxiliary gas: 55±2psi, curtain gas: 35±2psi, collision gas: 9±2psi, spray voltage: 5500±100V, inlet voltage: 10±2V, collision chamber outlet voltage: 6±2V, ion source temperature: 550±50℃, dwell time: 100±2msec, Resolution Q1: Unit, Resolution Q3: Unit.

[0055] Preferably, the mass spectrometry parameters include: ESI ion source, MRM positive ion mode, nebulizer gas: 55psi, heating auxiliary gas: 55psi, curtain gas: 35psi, collision gas: 9psi, spray voltage: 5500V, inlet voltage: 10V, collision chamber outlet voltage: 6V, ion source temperature: 550°C, dwell time: 100msec, Resolution Q1: Unit, Resolution Q3: Unit.

[0056] Furthermore, the impurity SM was found to have a retention time of 8.47 ± 0.5 min. 3a; The impurity Z is at a retention time of 5.11±0.5min 6k Each impurity can be qualitatively identified based on the retention time.

[0057] The third object of the present invention is to provide a method for detecting whether the content of genotoxic impurities in ibrutinib is qualified. The method has good stability and high accuracy, and provides support for the quality control of ibrutinib raw materials and subsequent preparations.

[0058] To achieve the above object, the present invention adopts the following technical solutions:

[0059] The method for detecting whether the content of genotoxic impurities in ibrutinib is qualified comprises the following steps:

[0060] (1) Prepare sample solution and reference solution;

[0061] (2) using the aforementioned identification method to detect the reference solution and the sample solution prepared in step (1) to obtain a chromatogram;

[0062] (3) constructing a chromatographic model based on the peak area of ​​the genotoxic impurity according to the chromatogram of the reference substance detected in step (2);

[0063] (4) Using the chromatographic model obtained in step (3), determine whether the genotoxic impurity content in the sample solution is qualified.

[0064] Furthermore, in step (1), acetonitrile is used as a diluent to prepare the test solution.

[0065] Preferably, the diluent is acetonitrile with a concentration of 50%.

[0066] Furthermore, the concentration of the reference solution is preferably 23.5 ng / ml.

[0067] Furthermore, the concentration of the sample solution is preferably 1 mg / ml.

[0068] As a preferred implementation case, the method specifically includes the following steps:

[0069] 1. Take about 50 mg of sample, weigh accurately, place in a 50 ml volumetric flask, add diluent to dissolve and dilute to scale, shake well, and use as sample solution;

[0070] 2. Take the impurity SM 3a and impurity Z 6k An appropriate amount of reference substance is accurately weighed, dissolved in a diluent and diluted to make a solution containing about 23.5 ng per 1 ml as the reference substance solution;

[0071] 3. Take the sample solution and the reference solution and inject them respectively, and detect them according to the above-mentioned chromatographic conditions and mass spectrometry conditions to obtain a chromatogram;

[0072] 4. According to the chromatogram obtained in step 3, ibrutinib and its genotoxic impurities were determined by the limit method.

[0073] Furthermore, if the sample solution contains impurities SM 3a and impurity Z 6k The peak area of ​​the impurity SM in the reference solution is not greater than 3a and impurity Z 6k The peak area of ​​SM indicates that the genotoxic impurity content in the sample solution is qualified; on the contrary, if the impurity SM in the sample solution is 3a and / or impurity Z 6k The peak area is larger than that of impurity SM in the reference solution. 3a and / or impurity Z 6k The peak area of ​​​​the sample solution is unqualified for genotoxic impurities.

[0074] The beneficial effects of the present invention are:

[0075] 1. The present invention provides a method for effectively determining the impurity SM in ibrutinib 3a and impurity Z 6k The present invention adjusts the LC-MS / MS gradient elution procedure to ensure that the impurity SM 3a and impurity Z 6k It can be well separated from ibrutinib and other impurities without interfering with the determination, and has good specificity.

[0076] 2. The method of the present invention can simultaneously separate and determine the impurity SM in Ibrutinib within 25 minutes 3a and impurity Z 6k , convenient and fast, with high accuracy and good method stability.

[0077] 3. The method of the present invention has the characteristics of high sensitivity, impurity SM 3a The detection limit concentration is as low as 5.64ng / ml, which is equivalent to 5.64ppm of impurities can be detected; impurity Z 6k The detection limit concentration is as low as 5.66 ng / ml, which is equivalent to 5.66 ppm of impurities being detectable, meeting the limit requirement of 23.5 ppm for the two genotoxic impurities. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 The blank solvent was in the impurity SM 3a Chromatogram of the channel;

[0079] Figure 2 The blank solvent contains impurity Z 6k Chromatogram of the channel;

[0080] Figure 3The detection limit solution is the impurity SM 3a Chromatogram of the channel;

[0081] Figure 4 The detection limit of the solution is impurity Z 6k Chromatogram of the channel;

[0082] Figure 5 For standard addition solution in impurity SM 3a Chromatogram of the channel;

[0083] Figure 6 Add the standard solution to the impurity Z 6k Chromatogram of the channel. DETAILED DESCRIPTION

[0084] The technical solution of the present invention will be further described clearly and completely in conjunction with specific embodiments below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present invention.

[0085] In the present invention, the sample solution is a solution whose main component is ibrutinib, and the sample solution contains impurities SM 3a 、Impurity Z 6k In addition, the sample solution may also contain other unspecified compounds, which refer to other impurities that may be introduced when preparing ibrutinib using conventional methods known in the art.

[0086] Unless otherwise specified, all numerical values ​​and similar values ​​used in the present invention to express parameters are understood to be modified by the term "about". That is, these numerical values ​​are allowed to have certain reasonable deviations or error ranges in practical applications, and do not have to strictly conform to the exact numerical values ​​given. Unless otherwise indicated, the numerical parameters described in the present invention are approximate values ​​that can be changed according to the performance required to be obtained.

[0087] Unless otherwise stated, terms or phrases involved in the present invention should not be considered as uncertain or unclear if there is no special definition, but should be understood according to the ordinary meaning in the art.

[0088] In the present invention, the term "LC-MS / MS", i.e. liquid chromatography-tandem mass spectrometry, is an analytical chemistry technique that combines the separation ability of liquid chromatography and the analytical ability of mass spectrometry. In liquid chromatography-tandem mass spectrometry, liquid chromatography is responsible for separating the analyte from the interfering substance, and mass spectrometry is responsible for detection. After sample injection, the sample first enters the chromatographic column under the carrying of the mobile phase, and after separation by the chromatographic column, enters the mass spectrometry for detection. The mass spectrometry is detected according to the mass-to-charge ratio of the analyte, and the analyte is converted into gaseous ions in the ion source and enters the mass spectrometry. In the triple quadrupole, the primary mass spectrometry scan allows specific ions to enter the collision chamber, and the molecular ions collide and decompose in the collision chamber to form daughter ions to enter the secondary mass spectrometry, and the secondary mass spectrometry scan allows specific fragment ions to enter the detector. LC-MS / MS technology is widely used in many fields such as bioanalysis, drug development, environmental science, and food safety because of its high sensitivity and high selectivity.

[0089] In the present invention, specificity, also known as selectivity or specificity, refers to the ability of the analytical method to accurately and selectively detect the component being measured when other components may be present in the sample. Specificity is a measure of mutual interference when the method is used for complex sample analysis. The present invention verifies whether the HPLC method has sufficient specificity to ensure accurate and unerring determination of the target analyte in complex samples.

[0090] In the present invention, the limit of detection (LOD) refers to the minimum concentration or amount of the target compound that the analytical method can reliably detect. The detection sensitivity of the HPLC method is determined, that is, the lowest concentration of the target analyte in the sample that can be identified. This helps to evaluate the reliability of the method at very low concentrations.

[0091] In the examples of the present invention, information on the compounds involved is shown in Table 1.

[0092] Table 1. Compound information

[0093]

[0094] In the embodiment of the present invention, the main instruments and equipment and experimental parameters are shown in Table 2.

[0095] Table 2. Summary of main instruments and experimental parameters

[0096]

[0097]

[0098] Table 3. Gradient elution schedule

[0099] Time (min) Mobile phase A Mobile phase B 0 60 40 6 60 40 6.1 40 60 10 40 60 10.1 1 99 20 1 99 20.1 60 40 25 60 40

[0100] Table 4. Mass-to-charge ratio information table

[0101] Target to be measured Precursor ion Product ions DP CE <![CDATA[Impurity SM 3a > 179.0 125.0 62 13 <![CDATA[Impurity Z 6k > 457.1 303.1 135 40

[0102] In the embodiments of the present invention, the determination was carried out strictly in accordance with the high performance liquid chromatography-mass spectrometry method (General Rules 0512 and General Rules 0431 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0103] Example 1

[0104] A LC-MS / MS method for separating and determining genotoxic impurities in ibrutinib specifically comprises the following steps:

[0105] (1) Prepare the test solution

[0106] Diluent: 50% acetonitrile.

[0107] Test sample solution: Take about 50 mg of the test sample, weigh accurately, place in a 50 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.

[0108] Reference solution: Take impurity SM 3a and impurity Z 6k An appropriate amount of reference substance is accurately weighed, dissolved in diluent and diluted to make a solution containing approximately 23.5 ng per 1 ml.

[0109] (2) Chromatographic conditions

[0110] Reverse phase amide bonded silica gel was used as filler (SUPELCO RP-Amide 4.6mm×150mm, 5μm, or a chromatographic column with equivalent performance); 0.1% formic acid aqueous solution as mobile phase A, acetonitrile as mobile phase B, gradient elution according to the above Table 3; flow rate 1ml per minute; column temperature 30℃; injection volume 20μl.

[0111] (3) Mass spectrometry conditions

[0112] A tandem quadrupole mass spectrometer was used with multiple reaction monitoring (MRM) in the positive ion mode of an electrospray ionization source (ESI). The mass-to-charge ratio (m / z) information is shown in Table 4 above.

[0113] (4) Determination

[0114] System suitability requirements: Select appropriate mass spectrometry conditions. In the chromatogram of the reference solution, the signal-to-noise ratio of the impurity peak should be no less than 20.

[0115] Determination method: Take the test solution and the reference solution and inject them directly, and record the chromatogram.

[0116] Limit: Impurity SM in the test solution3a and impurity Z 6k The peak area should not be greater than the impurity SM in the reference solution. 3a and impurity Z 6k Peak area (0.00235%).

[0117] Example 2. Specificity

[0118] (1) Prepare the test solution

[0119] Blank solvent: 50% acetonitrile.

[0120] Reference stock solution: Take impurity SM 3a and impurity Z 6k About 11.75 mg of each, accurately weighed, placed in respective 50 ml volumetric flasks, added diluent to dissolve and dilute to the scale, shake well, to obtain reference substance stock solution I; accurately pipette 0.5 ml of reference substance stock solution I, placed in the same 50 ml volumetric flask, added diluent to dilute to the scale, shake well, to obtain reference substance stock solution II.

[0121] Reference substance solution: Accurately pipette 0.5 ml of reference substance stock solution II into a 50 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.

[0122] Test sample solution: Take about 50 mg of the test sample, weigh accurately, place in a 50 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.

[0123] (2) Detection

[0124] Take blank solvent, reference solution and test solution, inject them into LC-MS / MS system respectively, and record the chromatogram.

[0125] The results are shown in Table 5. Figure 1-2 As shown, blank solvent and sample matrix did not interfere with the determination of impurities.

[0126] Table 5. Specificity test results

[0127] sample <![CDATA[Impurity SM 3a Retention time (min)]]> <![CDATA[Impurity Z 6k Retention time (min)]]> Reference solution 8.47 5.11 Test solution 8.47 5.11 Blank solvent At 8.47 minutes, there is no interference peak 5. At 11 minutes, there is no interference peak

[0128] Example 3. System Applicability

[0129] Take the reference solution under "Example 2. Specificity" as the system suitability solution, accurately measure 20 μl of the solution, inject it 6 times continuously, record the chromatogram, and calculate the RSD of the peak area.

[0130] The results are shown in Table 6. Impurity SM 3a and impurity Z 6k The RSDs of the peak areas were 2.0% and 0.6%, respectively.

[0131] Table 6. Results of system suitability test

[0132]

[0133] Example 4. Detection Limit

[0134] Accurately measure 1 ml of the reference solution under "Example 2. Specificity" and place it in a 5 ml centrifuge tube. Add 3 ml of diluent and shake well to obtain the detection limit solution. Repeat the injection three times in parallel and record the chromatogram.

[0135] The results are shown in Table 7. Figure 3-4 As shown, impurity SM 3a The detection limit concentration is 5.64ng / ml, which is equivalent to 5.64ppm of impurities can be detected; impurity Z 6k The detection limit concentration is 5.66 ng / ml, which is equivalent to 5.66 ppm of impurities being detected, meeting the limit requirement of 23.5 ppm for the two genotoxic impurities.

[0136] Table 7. Results of detection limit test

[0137]

[0138] Example 5. Standard addition test

[0139] (1) Prepare the test solution

[0140] Reference stock solution: Take impurity SM 3a and impurity Z 6k About 11.75 mg of each, accurately weighed, placed in respective 50 ml volumetric flasks, added diluent to dissolve and dilute to the scale, shake well, to obtain reference substance stock solution I; accurately pipette 0.5 ml of reference substance stock solution I, placed in the same 50 ml volumetric flask, added diluent to dilute to the scale, shake well, to obtain reference substance stock solution II.

[0141] Reference substance solution: Accurately pipette 0.5 ml of reference substance stock solution II into a 50 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.

[0142] Test sample solution: Take about 50 mg of the test sample, weigh accurately, place in a 50 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.

[0143] Standard addition solution: Take about 50 mg of the test sample, weigh it accurately, put it in a 50 ml volumetric flask, add 0.5 ml of reference substance stock solution II, add diluent to dissolve and dilute to the scale, shake well, and the standard addition solution is obtained.

[0144] (2) Detection

[0145] Take the reference solution, test solution and standard addition solution for sampling, measure each sample twice in parallel, and calculate the recovery rate.

[0146] The results are shown in Table 8. Figure 5-6 As shown, impurity SM 3a and impurity Z 6k The recoveries of the standard addition solutions were 95.3% and 98.7%, respectively. 3a and impurity Z 6k The determination has no effect.

[0147] Table 8. Results of standard addition test

[0148]

[0149] Example 6. Solution stability

[0150] (1) Prepare the test solution

[0151] Reference substance stock solution: take impurity SM 3a and impurity Z 6k About 11.75 mg of each, accurately weighed, placed in respective 50 ml volumetric flasks, added diluent to dissolve and dilute to the scale, shake well, to obtain reference substance stock solution I; accurately pipette 0.5 ml of reference substance stock solution I, placed in the same 50 ml volumetric flask, added diluent to dilute to the scale, shake well, to obtain reference substance stock solution II.

[0152] Reference substance solution: Accurately pipette 0.5 ml of reference substance stock solution II into a 50 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.

[0153] Standard addition solution: Take about 50 mg of the test sample, weigh it accurately, put it in a 50 ml volumetric flask, add 0.5 ml of reference substance stock solution II, add diluent to dissolve and dilute to the scale, shake well, and the standard addition solution is obtained.

[0154] (2) Detection

[0155] Take the standard added solution and the reference solution, record the chromatograms at 0h, 4h, 6h, and 10h, and calculate the peak area RSD.

[0156] The results are shown in Table 9. Impurity SM 3a and impurity Z 6k The reference solution and the standard spike solution were allowed to stabilize at room temperature for 10 hours.

[0157] Table 9. Results of solution stability test

[0158]

Claims

1. A method for separating genotoxic impurities in ibrutinib using LC-MS / MS, characterized in that: The genotoxic impurities include impurity SM 3a 、Impurity Z 6k Any one or two of the following; the structural formula of Ibrutinib is as shown in Formula I, the impurity SM 3a The structural formula is shown in Formula II, and the impurity Z 6k The structural formula is shown in Formula III; The LC-MS / MS method comprises: using reverse phase amide bonded silica gel as a chromatographic column filler, using formic acid water as a mobile phase A, and acetonitrile as a mobile phase B, and separating the genotoxic impurities in ibrutinib by gradient elution; 2. The method according to claim 1, characterized in that: The gradient elution was set up as follows: 0min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30; 6min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30; 6.1min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50; 10min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50; 10.1min, the volume ratio of the mobile phase A to the mobile phase B is 1-3:99-97; 20min, the volume ratio of the mobile phase A to the mobile phase B is 1-3:99-97; 20.1min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30; 25min, the volume ratio of the mobile phase A to the mobile phase B is 50-70:50-30.

3. The method according to claim 1, characterized in that The mobile phase A is a formic acid aqueous solution with a concentration of 0.05% to 0.2%.

4. The method according to claim 1, characterized in that: The column temperature of the chromatographic column is 30±2° C., and the flow rate of the mobile phase is 1±0.2 ml / min.

5. A method for identifying whether ibrutinib contains genotoxic impurities, characterized in that: The steps include: (1) separation: separating the genotoxic impurities in ibrutinib by the method described in any one of claims 1 to 4; (2) Detection: Detection is performed using a tandem quadrupole mass spectrometer to obtain a chromatogram; (3) Identification: Compare the chromatographic behavior of the test sample with that of the reference sample to determine whether the test sample contains genotoxic impurities.

6. The method according to claim 5, characterized in that In step (2), multiple reaction detection is performed in positive ion mode using an electrospray ion source.

7. The method according to claim 5, characterized in that The mass-to-charge ratio of 179.0→125.0 is used as the impurity SM 3a The detection ion pair is 457.1→303.1, and the impurity Z is used as 6k Detection ion pairs.

8. The method according to claim 5, characterized in that The impurity SM is at a retention time of 8.47±0.5min. 3a ; The impurity Z is at a retention time of 5.11±0.5min 6k .

9. A method for detecting whether the content of genotoxic impurities in ibrutinib is qualified, characterized in that: The steps include: (1) Prepare sample solution and reference solution; (2) using the method according to any one of claims 5 to 8 to detect the reference solution and the sample solution prepared in step (1) to obtain a chromatogram; (3) constructing a chromatographic model based on the peak area of ​​the genotoxic impurity according to the chromatogram of the reference substance detected in step (2); (4) Using the chromatographic model obtained in step (3), determine whether the genotoxic impurity content in the sample solution is qualified.

10. The method according to claim 9, characterized in that If the sample solution contains impurities SM 3a and impurity Z 6k The peak area of ​​the impurity SM in the reference solution is not greater than 3a and impurity Z 6k The peak area of ​​SM indicates that the genotoxic impurity content in the sample solution is qualified; on the contrary, if the impurity SM in the sample solution is 3a and / or impurity Z 6k The peak area is larger than that of the impurity SM in the reference solution. 3a and / or impurity Z 6k The peak area of ​​​​the sample solution is unqualified for genotoxic impurities.